ERRATUM

Erratum concerning Volume 14, Supplement 1, January 2008

ESBLs, Forever?
This publication represents the proceedings of the ESCMID Conference on Extended-spectrum Beta-lactamases and was published without commercial support. In the publication, some declarations concerning conflict of interest were not included. All declarations from all authors appear below.

Living with ESBLs
G. Cornaglia, J. Garau and D. M. Livermore
GC has received speaker fees and travel grants to lecture in symposia organised by Merck Sharp and Dohme, Wyeth and Pfizer; he declares no conflict of interest with respect to this publication. JG and DML make declarations below concerning their respective contributions.

Defining an extended-spectrum β-lactamase
D. M. Livermore
DML is employed within the UK public sector and is influenced by HPA and NHS policies and attitudes on prescribing; he has received grants and accepted lecture and conference invitations from numerous pharmaceutical companies and holds shares in several, with these amounting to less than 5% of a well-diversified portfolio. He does not believe that his comments in this paper have been materially influenced by these factors, or that these interests will be materially influenced by his comments in this paper.

Evolution of extended-spectrum β-lactamases by mutation
M. Gniadkowski
MG declares no conflict of interest regarding this publication and acknowledges support from the European Union for his work in the field of β-lactamases.

The spread of CTX-M-type extended-spectrum β-lactamases
G. M. Rossolini, M. M. D’Andrea and C. Mugnaioli
GMR, MMD and CM affirm that there are no conflicts of interest concerning the ideas expressed in this paper. All authors acknowledge research grants from the European Commision, the Italian Ministry of Research and University, and Wyeth Pharmaceuticals.

Minor extended-spectrum β-lactamases
T. Naas, L. Poirel and P. Nordmann
TN, LP and PN declare that they have no conflict of interest with respect to this paper.

IRT and CMT β-lactamases and inhibitor resistance
R. Cantón, M. I. Morosini, O. Martin, S. de la Maza and E. G. G. de la Pedrosa
RC has received grants from Wyeth and Sanofi Aventis and consultancy fees from Novartis; he declares no conflicting or dual interests concerning this paper. MIM, OM, SM and EGGP declare no conflicting or dual interests in relation to the work or opinions presented in this paper.

Extended-spectrum β-lactamases: structure and kinetic mechanism
M. G. P. Page
MGPP declares that he has not received speaker fees or research funding related to the subject of this review and has not received travel grants in the last 2 years.
Genetic support of extended-spectrum β-lactamases
L. Poirel, T. Naas and P. Nordmann
LP, TN and PN declare that they have no conflict of interest with respect to this paper.

Extended-spectrum β-lactamases and the permeability barrier
L. Martínez-Martínez
LM-M has served as a consultant for Wyeth, has been a speaker for Chiron, Wyeth and GSK, has received research support from Chiron, Wyeth, GSK, MSD and Pfizer, and declares that he has no conflicting or dual interests in relation to the work or opinions presented in this paper.

Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guide
L. Drieux, F. Brossier, W. Sougakoff and V. Jarlier
LD, FB, WS and VJ declare no conflicts of interest.

Extended-spectrum β-lactamases in ambulatory care: a clinical perspective
J. Rodríguez-Banño and M. D. Navarro
JR-B has been a consultant for Wyeth, Merck, Pfizer, and GlaxoSmithKline, and affirms that there is no conflict of interest concerning the ideas expressed in this paper. MDN declares that she has no conflicting or dual interests in relation to the work or opinions presented in this paper.

Extended-spectrum β-lactamases in long-term-care facilities
M.-H. Nicolas-Chanoine, V. Jarlier
M-H N-C and VJ declare that they have no conflicting or dual interests in relation to the work or opinions presented in this paper.

Animal reservoirs for extended spectrum β-lactamase producers
A. Carattoli
AC declares that she has no conflicting interests in relation to the opinions presented in this paper.

Control of infections due to extended-spectrum β-lactamase-producing organisms in hospitals and the community
R. E. Warren, G. Harvey, R. Carr, D. Ward and A. Doroshenko
REW has received speaker fees and support to attend meetings and a grant for audit of cases of ESBL infection from Merck and Co., manufacturers of carbapenems. GH has received speaker fees, consultancy fees and support to attend meetings from Merck and Co. No conflict of interest with respect to this paper was declared by RC, DW and AD.

K. Bush
KB is an employee of Johnson and Johnson Pharmaceutical Research and Development and declares that there is no conflict of interest concerning the scientific content and the ideas expressed in this paper.
Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero and T. M. Coque
RC has received grants from Wyeth and Sanofi Aventis and consultancy fees from Novartis; he declares no conflicting or dual interests concerning this paper. AN, AV, EM, LP, FB and TMC declare no conflicting or dual interests in relation to the work or opinions presented in this paper. All authors acknowledge funding support from the Ministerio de Sanidad y Consumo and Ministerio de Ciencia y Tecnología, Spain and from the European Union.

Prevalence of extended-spectrum β-lactamases in South America
M. V. Villegas, J. N. Kattan, M. G. Quinteros and J. M. Casellas
MVV has received grants for research and honorariums from MSD, Pfizer, Wyeth, BMS and Baxter, and declares no conflict of interest concerning the ideas expressed in this paper. JNK, MGQ and JMC declare that they have received no funding and that they have no conflicts of interest.

Prevalence and clonality of extended-spectrum β-lactamases in Asia
P. M. Hawkey
PMH acknowledges support from the British Society for Antimicrobial Therapy, British Council, University Grant Commission, India, the Royal Thai Government, Merck and Wyeth for work undertaken.

Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriaceae:
pharmacokinetic/pharmacodynamic considerations
A. MacGowan
AM declares no conflicts of interest.

Breakpoints for intravenously used cephalosporins in Enterobacteriaceae—EUCAST and CLSI breakpoints
G. Kahlmeter
GK is a consultant with or advisor to the following commercial organisations: CLSI (Clinical Laboratory Standards Institute), USA., UKNEQAS (United Kingdom National Quality Assessment System), UK, Oxoid Ltd, UK, Becton-Dickinson, USA, BioMerieux, France and declares no conflict of interest with any of the companies involved in the production or sale of drugs directly affected by ESBLs.

Parenteral carbapenems
P. M. Shah
PMS has received honoraria for consultation and/or lectures in 2007 from Pfizer, Wyeth and sanofi-aventis.

Antibiotic policy and prescribing strategies for therapy of extended-spectrum β-lactamase-producing Enterobacteriaceae: the role of piperacillin–tazobactam
L. R. Peterson
LRP has lectured for Wyeth Pharmaceuticals and has received funding for research from Wyeth Pharmaceuticals.

Sulbactam-containing β-lactamase inhibitor combinations
M. Akova
MA acknowledges research funding from Merck Sharp and Dohme and Pfizer, speaker fees from Wyeth and Pfizer, and travel grants from Merck Sharp and Dohme, Wyeth, Sanofi-Aventis and Pfizer.
including a grant to attend the meeting at which this paper was presented; he declares no conflict of interest concerning the views expressed.

Orthodox and unorthodox clavulanate combinations against extended-spectrum $\beta$-lactamase producer
D. M. Livermore, R. Hope, S. Mushtaq and M. Warner
DML is employed within the UK public sector and is influenced by HPA and NHS policies and attitudes on prescribing; he has received grants and accepted lecture and conference invitations from numerous pharmaceutical companies and holds shares in several, with these amounting to less than 5% of a well-diversified portfolio. He does not believe that his comments in this paper have been materially influenced by these factors, or that these interests will be materially influenced by his comments in this paper. No conflict of interest with respect to this paper was declared by RH, SM and MW.

$\beta$-Lactams without a suicide inhibitor
H. Giamarellou
HG has received consulting fees from Wyeth as well as research grants from Elli–Lilly, Sanofi–Aventis, Abbott, Pfizer and Novartis, independent of the topic of this paper, and declares no conflict of interest.

Other antimicrobials of interest in the era of extended-spectrum $\beta$-lactamases: fosfomycin, nitrofurantoin and tigecycline
J. Garau
JG has acted as a paid consultant to: GlaxoSmithKline, Bayer, MSD, Wyeth Lederle and Sanofi-Aventis. He has received funding for research from Wyeth, Lederle (unrelated to this article) and GlaxoSmithKline.